PRCT vs. NVO
Compare and contrast key facts about PROCEPT BioRobotics Corporation (PRCT) and Novo Nordisk A/S (NVO).
Scroll down to visually compare performance, riskiness, drawdowns, and other indicators and decide which better suits your portfolio: PRCT or NVO.
Key characteristics
PRCT | NVO | |
---|---|---|
YTD Return | 95.63% | 33.52% |
1Y Return | 149.82% | 45.06% |
3Y Return (Ann) | 27.19% | 39.91% |
Sharpe Ratio | 2.50 | 1.41 |
Daily Std Dev | 58.96% | 30.64% |
Max Drawdown | -63.51% | -51.96% |
Current Drawdown | -1.74% | -6.46% |
Fundamentals
PRCT | NVO | |
---|---|---|
Market Cap | $4.21B | $609.93B |
EPS | -$2.06 | $2.98 |
Total Revenue (TTM) | $176.58M | $258.00B |
Gross Profit (TTM) | $94.06M | $218.09B |
EBITDA (TTM) | -$105.87M | $130.97B |
Correlation
The correlation between PRCT and NVO is 0.20, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.
Performance
PRCT vs. NVO - Performance Comparison
In the year-to-date period, PRCT achieves a 95.63% return, which is significantly higher than NVO's 33.52% return. The chart below displays the growth of a $10,000 investment in both assets, with all prices adjusted for splits and dividends.
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Risk-Adjusted Performance
PRCT vs. NVO - Risk-Adjusted Performance Comparison
This table presents a comparison of risk-adjusted performance metrics for PROCEPT BioRobotics Corporation (PRCT) and Novo Nordisk A/S (NVO). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Dividends
PRCT vs. NVO - Dividend Comparison
PRCT has not paid dividends to shareholders, while NVO's dividend yield for the trailing twelve months is around 0.75%.
TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
PROCEPT BioRobotics Corporation | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Novo Nordisk A/S | 0.75% | 0.18% | 0.21% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Drawdowns
PRCT vs. NVO - Drawdown Comparison
The maximum PRCT drawdown since its inception was -63.51%, which is greater than NVO's maximum drawdown of -51.96%. Use the drawdown chart below to compare losses from any high point for PRCT and NVO. For additional features, visit the drawdowns tool.
Volatility
PRCT vs. NVO - Volatility Comparison
PROCEPT BioRobotics Corporation (PRCT) has a higher volatility of 26.81% compared to Novo Nordisk A/S (NVO) at 7.10%. This indicates that PRCT's price experiences larger fluctuations and is considered to be riskier than NVO based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Financials
PRCT vs. NVO - Financials Comparison
This section allows you to compare key financial metrics between PROCEPT BioRobotics Corporation and Novo Nordisk A/S. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities